Insurers Are Pulling Back From GLP-1 Drugs. The FDA Just Handed Eli Lilly Its Best Weapon Yet

Omor Ibne Ehsan

Tue, September 1, 2026 at 5:40 PM GMT+3 3 min read

Quick Read

The FDA's Mounjaro cardiovascular label gives LLY medical-necessity language to defend diabetes reimbursement as employer GLP-1 coverage drops from 72% to 60%.
Mounjaro Q2 revenue surged 91% to nearly $10 billion, with volume growth offsetting price declines as Lilly raises full-year guidance to $87 billion.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today.

Employer coverage of GLP-1 weight-loss drugs fell from 72% in 2025 to 60% in 2026, and roughly 14% of surveyed employers have already dropped the medicines or plan to do so in 2027. That is the pressure squeezing the entire category.

Courtesy of Novo Nordisk

Against that retreat, Eli Lilly (NYSE:LLY) just received something it can actually use in a payer meeting. On August 28, 2026, the FDA expanded Mounjaro's label to reduce the risk of cardiovascular death, heart attack, and stroke in adults with type 2 diabetes at high cardiovascular risk. This is a diabetes label rather than a Zepbound obesity label, and the distinction matters for how much of the coverage rollback it can actually blunt.

What the Label Really Says

The underlying trial enrolled more than 13,000 patients and found 8% fewer major cardiovascular events with Mounjaro than with Lilly's older Trulicity. An 8% relative reduction is real, but it is measured against another active GLP-1 rather than placebo, so the comparison tells payers that Mounjaro edges out an established therapy instead of proving that GLP-1s save lives from a standing start.

That nuance is why the label helps most where cardiovascular risk is already priced into premiums: diabetes case management, not general obesity coverage. Employers dropping GLP-1s are mostly cutting Zepbound-style weight-loss benefits, which this approval does not touch.

Still, the cardiovascular data gives Lilly a durable argument that treating comorbid diabetes prevents downstream hospital spending, and that argument travels.

LLY Price Target — 24/7 Wall St.

Numbers Behind the Argument

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today.

Mounjaro revenue rose 91% in the second quarter to $9.94 billion, with U.S. growth of 45% and international growth of 172% following China's addition of it to the national reimbursement list.

Total revenue reached $22.97 billion, and Lilly raised full-year guidance to $85.0 billion to $87.0 billion. CEO David Ricks said, "Lilly's momentum continues, as we delivered 48% revenue growth and raised our full-year guidance."

LLY Earnings Explorer — 24/7 Wall St.

Volume is driving the growth while pricing declines. U.S. price declined 9% excluding rebate adjustments, and CFO Lucas Montarce told investors, "expect that price will actually go down for sure ... we are going to more than offset that with volume growth."

LLY Analyst Ratings — 24/7 Wall St.

Position on the Central Question

The label likely protects diabetes reimbursement more than it reopens obesity coverage. Approval does not compel a single insurer or employer to pay for anything, and pretending otherwise misreads how formularies work.

But it does give Lilly medical-necessity language for the diabetes patients most likely to be cut in a cost review, and, combined with the Medicare Bridge Program covering 20 million eligible Americans at $50 per month, it meaningfully narrows the exposure.

Shares trade at $1,174.61 and 32x forward earnings, with an analyst target of $1,315.04. The stock is down 6.44% in the past week, so the market has not yet priced the cardiovascular claim as a coverage shield. If Lilly can turn the label into contract language rather than press releases, that gap closes.